New COPD combo shows promise in early trial

NCT ID NCT07132983

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new combination of two inhaled drugs, ensifentrine and glycopyrrolate, in 33 adults with COPD. The goal was to see how the drugs move through the body, how well they open airways, and if they are safe. Each person received single doses of the combination and each drug alone. The results will help decide if this combo should be tested further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ensifentrine and glycopyrrolate (inhaled drugs)
What this could lead to
If successful, this combination could offer a new option to help people with COPD breathe easier by opening airways and reducing inflammation.
What could go wrong
This is a small, early-phase study (33 people) looking at short-term effects. It may not lead to a better treatment, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Research of West Florida Inc - Clearwater

    Clearwater, Florida, 33765-2616, United States

  • Clinical Research of West Florida Inc - Tampa

    Tampa, Florida, 33606-1246, United States

  • Midwest Chest Consultants PC

    Saint Charles, Missouri, 63301, United States

  • Velocity Clinical Research - Spartanburg - PPDS

    Spartanburg, South Carolina, 29303-4225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.